Thrombotic microangiopathy with renal dysfunction is a haematological and renal emergency warranting urgent diagnosis and intervention. As the potential underlying causes may be complex, assessment and management can be challenging for treating clinicians, and a timely and collaborative approach between general physicians, haematologists and nephrologists may be extremely helpful in order to optimise clinical outcomes. This paper will aim to build an understanding of different potential presentations of thrombotic microangiopathies and provide a practical framework for diagnosis and management, using a case-based discussion format, for acute and general physicians. Some aspects of subsequent specialist management are also discussed.
BrandtJR, FouserLS, WatkinsSL. Escherichia coli O 157: H7-associated hemolytic-uremic syndrome after ingestion of contaminated hamburgers. J Pediatr1994; 125: 519–26.
20.
LoosS, AulbertW, HoppeB. intermediate follow-up of pediatric patients with hemolytic uremic syndrome during the 2011 outbreak caused by E. coli O104: H4. Clin Infect Dis2017; 64: 1637–43.
GeorgeJN, NesterCM, McIntoshJJ. Syndromes of thrombotic microangiopathy associated with pregnancy. Hematol Am Soc Hematol Educ Program2015; 2015: 644–8.
31.
FakhouriF, VercelC, Fremeaux-BacchiV. Obstetric nephrology: AKI and thrombotic microangiopathies in pregnancy. Clin J Am Soc Nephrol2012; 7: 2100–6.
32.
ChenM-H, ChenM-H, ChenW-S. Thrombotic microangiopathy in systemic lupus erythematosus: a cohort study in North Taiwan. Rheumatology2010; 50: 768–75.
33.
BrocklebankV, KavanaghD. Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea. Clin Kidney J2017; 10: 600–24.
34.
WoodworthTG, SulimanYA, LiW. Scleroderma renal crisis and renal involvement in systemic sclerosis. Nat Rev Nephrol2016; 12: 678–91.
35.
ScullyM. Cancer and thrombotic microangiopathy. J Oncol Pract2016; 12: 531–2.
36.
IzzedineH, PerazellaMA. Thrombotic microangiopathy, cancer, and cancer drugs. Am J Kidney Dis2015; 66: 857–68.
GeorgeJN. Systemic malignancies as a cause of unexpected microangiopathic hemolytic anemia and thrombocytopenia. Oncology2011; 25: 908–14.
39.
AbbasF, El KossiM, KimJJ. Thrombotic microangiopathy after renal transplantation: Current insights in de novo and recurrent disease. World J Transplant2018; 8: 122–41.
40.
NorisM, RemuzziG. Thrombotic microangiopathy after kidney transplantation. Am J Transplant2010; 10: 1517–23.
41.
GargN, RennkeHG, PavlakisM. De novo thrombotic microangiopathy after kidney transplantation. Transplant Rev2018; 32: 58–68.
42.
JavaA, EdwardsA, RossiA. Cytomegalovirus-induced thrombotic microangiopathy after renal transplant successfully treated with eculizumab: case report and review of the literature. Transpl Int2015; 28: 1121–5.
ShavitL, ReinusC, SlotkiI. Severe renal failure and microangiopathic hemolysis induced by malignant hypertension—case series and review of literature. Clin Nephrol2010; 73: 147–52.
